Danielle E Hammond, MD, FRCP(C) HEMATOLOGY
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Postgraduate Training
| 2019-2021 | Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2017-2019 | Clinical Residency, Adult Hematology, Queen's University, Kingston |
| 2014-2017 | Clinical Residency, Internal Medicine, University of Toronto, Toronto |
Board Certifications
| 2019 | The Royal College of Physicians and Surgeons of Canada Certification in Adult Hematology |
| 2018 | The Royal College of Physicians and Surgeons of Canada Certification in Internal Medicine |
| 2016 | Licentiate, Medical Council of Canada |
| 2014 | United States Medical Licensing Exam, Step 2 Clinical Knowledge |
Selected Publications
Peer-Reviewed Articles
- DiNardo CD, Venugopal S, Lachowiez CA, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway HE, Sekeres MA, Sukkur A, Hammond D, Chien KS, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia TM, Short NJ, Daver NG, Borthakur G, Ravandi F, Kantarjian HM, Patel BJ, DeZern AE, Roboz GJ, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. e-Pub 2022. PMID: 35973199.
- Chua CC, Hammond D, Kent A, Tiong IS, Konopleva MY, Pollyea DA, DiNardo CD, Wei AH. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv 6(13):3879-3883, 2022. PMID: 35511730.
- Mouhayar EN, Hammond D, Lopez-Mattei J, Banchs J, Konopleva M, Pemmaraju N. Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome. JACC CardioOncol 3(5):752-755, 2021. e-Pub 2021. PMID: 34988487.
- Hammond D, Montalban-Bravo G. Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia. Curr Hematol Malig Rep 16(5):405-417, 2021. e-Pub 2021. PMID: 34499330.
- Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. e-Pub 2021. PMID: 33846541.
- Hammond D, Loghavi S. Clonal haematopoiesis of emerging significance. Pathology 53(3):300-311, 2021. e-Pub 2021. PMID: 33685721.
- Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol 96(2):E50-E53, 2021. e-Pub 2020. PMID: 33156969.
- Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of Venetoclax-Based Therapy in Chronic Myelomonocytic Leukemia. Leukemia, 2021. PMID: 33846541.
- Hammond D, Pemmaraju N. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am 34(3):565-574, 2020. e-Pub 2020. PMID: 32336420.
- Mouhayar E, Hammond D, Lopez-Mattei J, Banchs J, Konopleva M, Pemmaraju N. . Reversible Myocardial Edema Secondary to Tagraxofusp-induced Capillary Leak Syndrome. JACC: CardioOncology.
Abstracts
- Hammond D, Kadia TM, DiNardo CD, Konopleva M, Short NJ, Daver N, Ravandi F, Pemmaraju N, Jabbour E, Chien K, Pierce S, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia, 2021.
- Chua CC, Hammond D, Kent A, Tiong IS, Ong DM, Konopleva M, Pollyea D, Dinardo CD, Wei AH. Treatment Free Remission After Ceasing Venetoclax-based Therapy in Responding Patients with Acute Myeloid Leukemia, 2021.
- Hammond D, Sasaki K, Geppner A, Haddad F, Mohamed S, Rivera D, Siddiqui M, Alwash Y, Ramos Perez J, Morita K, Kim K, Pierce S, Gutierrez C, Pemmaraju N, Borthakur G, Dinardo CD, Ravandi F, Garcia-Manero G, Kantarjian H, Kadia TM. Contemporary Outcomes for Adults with AML Requiring ICU Admission, 2021.
- Hammond D, Loghavi S, Konopleva M, Kadia TM, Daver N, Ohanian M, Issa GC, Alvarado Y, Montalban-Bravo G, Garcia-Manero G, Borthakur G, Ravandi F, Takahashi K, Kantarjian H, DiNardo CD.. Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents, 2020.
- Hammond D, DiNardo CD, Konopleva M, Borthakur G, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Paul S, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation, 2020.
- Guerra V, Ramos Perez J, Hammond D, Chien K, Kanagal-Shamanna R, Naqvi K, Sasaki K, Paul S, Kadia TM, DiNardo CD, Konopleva M, Daver N, Ravandi F, Pemmaraju N, Short NJ, Issa GC, Takahashi K, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Outcomes of Chronic Myelomonocytic Leukemia after Hypomethylating Agent Failure, 2020.
- Teichman J, Hammond D, Fenech S, Sholzberg M. Effect of Direct Oral Anticoagulants on Fibrinogen Induced Pseudoparaproteinemia, 2018.
- Hammond D, Jamali M, Wells RA, Zhang L, Mamedov A, Lenis M, Buckstein R. Impact of Bone Marrow Fibrosis in MDS Patients Treated with Azacitidine, 2016.
- Hammond D, Saidenberg E, Tinmouth A. Single Centre Experience with Rituximab in the Treatment of Inhibitor‐Associated Hemostatic Disorders, 2015.
Grant & Contract Support
| Title: | Targeting Clonal Hematopoiesis (CH) to Prevent Acute Myeloid Leukemia (AML) |
| Funding Source: | Break Through Sponsor |
| Role: | Co-Principal Investigator |